Endocrine Abstracts (2006) 11 P546

Cell proliferation and outcome of GH-secreting pituitary adenomas

L De Marinis1, A Bianchi1, L Tilaro1, F Doglietto2, F Veltri1, GV Vellone3, F Lugli1, A Fusco1, V Cimino1, A Pontecorvi1 & L Lauriola1


1Endocrinology, Rome, Italy; 2Neurosurgery, Rome, Italy; 3Pathology; Catholic University School of Medicine, Rome, Italy.


In order to investigate the correlations between immunohistochemical picture with proliferative index (Ki-67), the clinical course and outcome of GH-secreting pituitary adenomas not cured by neurosurgery, we studied 41 consecutive acromegalic patients (M 12, F 29; aged 43±10.8 yr) previously undergone neurosurgical resection of adenoma. Two patients underwent neurosurgical intervention at least twice. Post-surgical follow-up ranged from 6 to 36 months and all patients received medical treatment with somatostatin analogs because relapse or persistence of disease. Ki-67 determination was effectuated on 43 surgical specimens. Patients were divided in 2 groups according to Ki-67 value of the surgical specimen (≤1% or >1%).

The first group (Ki-67 ≤1%) was composed by 23 patients (M8; F15; aged 45±2 yrs.; 20 Macro- and 3 microadenomas), one of which underwent two neurosurgical resections. The mean value of IGF-I before surgery was 634±52 ng/ml, while during follow-up was 280±31 ng/ml. At last neuroradiological control, 5 patients (21.7%) showed residue/relapse of desease, while 18 (78.3%) of them had a negative magnetic resonance imaging (MRI). The second group (Ki-67 >1%) was composed by 19 patients (M 4; F 15; aged 41±3 yrs. 18 Macro- and 1 microadenomas), one of which underwent two neurosurgical resections. The mean value of IGF-I before surgery was 814.2±58 ng/ml, while during follow-up was 456±59 ng/ml. At last neuroradiological control 11 (61.1%) patients showed residue/relapse of desease, while 7 (38.9%) of them had a negative MRI. Our results showed that ki-67 index seems to be related to prognosis of GH-secreting adenomas in terms of both neurosurgical outcome and biochemical response to somatostatin analogs, independently from size of adenomas and age at diagnosis.

Article tools

My recent searches

No recent searches.